Skyrizi (risankizumab) vs Idacio (adalimumab-aacf)

Skyrizi (risankizumab) and Idacio (adalimumab-aacf) are both used for the treatment of certain inflammatory conditions, such as plaque psoriasis and rheumatoid arthritis, but they work in different ways: Skyrizi is an interleukin-23 inhibitor that targets a specific pathway in the immune system, while Idacio, a biosimilar to Humira, is a TNF inhibitor that blocks a broader range of inflammatory processes. Skyrizi is typically administered once every 12 weeks after two initial doses, offering a less frequent dosing schedule, whereas Idacio requires more frequent administration, usually every other week. The choice between Skyrizi and Idacio may depend on the individual's specific condition, response to previous treatments, the preferred frequency of administration, and potential side effects, which should be discussed with a healthcare provider.

Difference between Skyrizi and Idacio

Metric	Skyrizi (risankizumab)	Idacio (adalimumab-aacf)
Generic name	Risankizumab	Adalimumab-aacf
Indications	Plaque psoriasis, psoriatic arthritis	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis
Mechanism of action	IL-23 inhibitor	TNF inhibitor
Brand names	Skyrizi	Idacio
Administrative route	Subcutaneous injection	Subcutaneous injection
Side effects	Upper respiratory infections, headache, fatigue, injection site reactions	Infections, injection site reactions, headache, rash, nausea
Contraindications	Known hypersensitivity to risankizumab or excipients	Known hypersensitivity to adalimumab or excipients, active tuberculosis, severe infections
Drug class	Monoclonal antibody	Monoclonal antibody
Manufacturer	AbbVie Inc.	Fresenius Kabi

Efficacy

Efficacy of Skyrizi (risankizumab) in Psoriatic Arthritis

Skyrizi (risankizumab) is a biologic medication approved for the treatment of moderate to severe plaque psoriasis. It is an interleukin-23 (IL-23) inhibitor that works by targeting a specific protein involved in the inflammatory process of psoriasis. While Skyrizi has been shown to be effective in treating plaque psoriasis, its efficacy in psoriatic arthritis is currently being evaluated. Clinical trials are underway to determine the safety and effectiveness of risankizumab in patients with psoriatic arthritis, a condition characterized by joint pain and swelling in conjunction with skin psoriasis.

Initial data from clinical trials suggest that Skyrizi may help in reducing the signs and symptoms of psoriatic arthritis, improving physical function, and inhibiting the progression of joint damage. However, as of the current knowledge cutoff, Skyrizi has not yet received approval for the treatment of psoriatic arthritis. Healthcare providers and patients are advised to monitor ongoing research and clinical trial results for more definitive information regarding the efficacy of Skyrizi in this specific condition.

Efficacy of Idacio (adalimumab-aacf) in Psoriatic Arthritis

Idacio (adalimumab-aacf) is a biosimilar to the reference product adalimumab, commonly known as Humira. Adalimumab is a tumor necrosis factor (TNF) inhibitor that has been widely used and proven effective in treating several inflammatory conditions, including psoriatic arthritis. As a biosimilar, Idacio has demonstrated no clinically meaningful differences in terms of safety, purity, and potency in comparison to its reference product. It is approved for all the same indications as the original adalimumab, including the treatment of psoriatic arthritis.

In clinical practice, Idacio has shown to reduce the signs and symptoms of psoriatic arthritis, improve physical function, and prevent further joint damage. Patients treated with Idacio have reported significant improvements in joint pain, stiffness, and swelling. The efficacy of Idacio in psoriatic arthritis makes it a valuable treatment option for patients suffering from this chronic and often debilitating condition. As with all medications, the decision to use Idacio should be made by a healthcare provider in consultation with the patient, considering all individual health factors and treatment goals.

Regulatory Agency Approvals

Skyrizi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Idacio

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Skyrizi or Idacio today

If Skyrizi or Idacio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Skyrizi

Buy Idacio

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: